The collaboration is expected to increase the annual production capability of Sr-82 produced at INR and thereafter increase supply to key markets.
Initial shipments of Sr-82 samples are expected at the MIT Facility in Lubbock, Texas in the spring of 2012.
These samples will be processed at MIT for final purification into Active Pharmaceutical Ingredient (API).
MIT president Jason Kitten said through INR’s production expertise and reliability of supply, the growth of Sr-82 was possible, making the Sr82/Rb82 generator a mainstream modality for cardiac perfusion imaging.